Develop succession and illness plans

Sarbox has had some obvious side effects, one of which is greater focus on nonfinancial risks, such as CEO succession. If your company doesn't have one, you should push for one immediately. You might be surprised how many boards avoid the issue. Here is a tricky area: What about illnesses? Some shareholders would argue that serious physical impairment to the CEO, and perhaps other top executives, should be disclosed. They have a point: the share price stands to be significantly affected--and that's likely your bailiwick. So you have a stake in all this. A few companies have considered requiring CEOs to disclose more health information. So far such requirements haven't made it into contracts, but it's worth considering. Article